Drug Profile


Alternative Names: ENPAXIQ; ONX-0803; Pacritinibum; SB-1518

Latest Information Update: 18 Apr 2017

Price : $50

At a glance

  • Originator S*BIO
  • Developer Cardiff University; CTI BioPharma; National Cancer Research Institute; Ohio State University Comprehensive Cancer Center; S*BIO; University of California, San Diego; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Macrocyclic compounds; Polycyclic bridged compounds; Pyrimidines; Pyrrolidines; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Interleukin-1 receptor-associated kinase inhibitors; Janus kinase-2 inhibitors; Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myeloproliferative disorders; Myelofibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Myelofibrosis
  • Phase II Acute myeloid leukaemia; Colorectal cancer; Myelodysplastic syndromes; Myeloproliferative disorders
  • Phase I/II Graft-versus-host disease
  • Phase I Haematological disorders
  • Preclinical Chronic myeloid leukaemia
  • Discontinued Lymphoma

Most Recent Events

  • 30 Mar 2017 Phase-I/II clinical trials in Graft-versus-host disease (Combination therapy, Prevention) in USA (PO) (NCT02891603)
  • 20 Feb 2017 Regulatory submission withdrawn for Myelofibrosis in European Union (PO) to accumulate and provide additional data
  • 09 Jan 2017 Pacritinib is available for licensing in territories excluding USA as of 09 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top